Navigating key news stories in pharma

Featured Stories

Featured
Unlocking the Potential of Next-Gen Therapies with Advanced Technology
Future Biopharma
Unlocking the Potential of Next-Gen Therapies with Advanced Technology
Future Biopharma

The complexities of next-generation therapies are pushing the boundaries of development and manufacture, leading to an increased need for advanced technologies and novel approaches to processes.

Read More →
Future Biopharma
News
Serving as a Gateway to the Americas’ Pharma Market
Strategy
Serving as a Gateway to the Americas’ Pharma Market
Strategy

In this interview, Sarah Griffin from Informa Markets provides a review of CPHI Americas 2025 and teases some potential exciting innovations being planned for the 2026 edition of the conference.

Strategy
BIO 2025: Getting to the Root of Cardiopulmonary Diseases with Epigenetic Modulation
Future Biopharma
BIO 2025: Getting to the Root of Cardiopulmonary Diseases with Epigenetic Modulation
Future Biopharma

Epigenetic modulation has been important in the development of oncology therapies, but its use in cardiovascular diseases is just beginning. In this pre-BIO interview, Sten Sörensen from Cereno Scientific provides some insights into developments in this field.

Future Biopharma
BIO 2025: Making Biologics Manufacturing Accessible
Future Biopharma
BIO 2025: Making Biologics Manufacturing Accessible
Future Biopharma

Prior to BIO 2025, Russell Miller from Enzene Biosciences highlights how a fully connected continuous manufacturing platform is enhancing biologics production and, hence, improving patient access.

Future Biopharma

Dealmaking

Featured
Sanofi Enters into Agreement to Acquire Blueprint Medicines
Sanofi Enters into Agreement to Acquire Blueprint Medicines

The proposed acquisition will expand Sanofi’s immunological portfolio with a precision medicine already approved for the treatment of ASM and ISM, a next-gen highly selective kinase inhibitor, and an investigational oral drug.

CDMO Forms Strategic Collaborations for Cell-Based Therapies in Eye Disease and Solid Tumors
CDMO Forms Strategic Collaborations for Cell-Based Therapies in Eye Disease and Solid Tumors

Porton Advanced has announced separate partnerships with TongEYE and Hualong Biological, as it moves into regenerative therapies for vision loss and innovative immunotherapies for solid tumors.

Regeneron to Buy Bankrupt DNA Testing Firm
Regeneron to Buy Bankrupt DNA Testing Firm

The court supervised purchase, which is still subject to relevant conditions, will see Regeneron acquire the assets of 23andMe, except for its Lemonaid Health business.

GSK Acquires Promising Liver Disease Drug in USD 2 Billion Deal
GSK Acquires Promising Liver Disease Drug in USD 2 Billion Deal

The acquisition of efimosfermin alfa, a Phase III-ready FGF21 analog targeting steatotic liver diseases, will expand GSK’s hepatology pipeline and establish a best-in-class therapy for MASH and ALD.

Future Biopharma

Featured
BIO 2025: Getting to the Root of Cardiopulmonary Diseases with Epigenetic Modulation
BIO 2025: Getting to the Root of Cardiopulmonary Diseases with Epigenetic Modulation

Epigenetic modulation has been important in the development of oncology therapies, but its use in cardiovascular diseases is just beginning. In this pre-BIO interview, Sten Sörensen from Cereno Scientific provides some insights into developments in this field.

BIO 2025: Making Biologics Manufacturing Accessible
BIO 2025: Making Biologics Manufacturing Accessible

Prior to BIO 2025, Russell Miller from Enzene Biosciences highlights how a fully connected continuous manufacturing platform is enhancing biologics production and, hence, improving patient access.

BIO 2025: Targeting the Microenvironment to Treat Solid Tumors
BIO 2025: Targeting the Microenvironment to Treat Solid Tumors

Solid tumors are difficult to treat as a result of numerous factors, in this interview, Oury Chetboun from Seekyo Therapeutics, details how targeting functional proteins in the tumor microenvironment can help.

BIO 2025: Tackling Metastatic Tumors with Radiotherapeutics
BIO 2025: Tackling Metastatic Tumors with Radiotherapeutics

Treating metastases with an external laser beam can prove challenging; however, radiotherapeutics are providing more targeted treatment options, radiating the tumor cells from within, specifies David Bejker from Affibody.

BioDuro Banner
Touchlight Banner

R&D

Featured
Dicot Pharma Unveils MoA Findings for Potency Therapy
Dicot Pharma Unveils MoA Findings for Potency Therapy

The latest studies on the mechanism of action for LIB-01 have demonstrated that the drug targets the underlying nerves and vascular structures that are involved in penile erections.

New Data Demonstrates Unique Expression Profile of RNA Platform
New Data Demonstrates Unique Expression Profile of RNA Platform

Circio presented the enhanced in vivo data for its circVec platform in viral and non-viral vectors at ASGCT 2025.

Accure Therapeutics Granted USD 1.6 Million to Advance Parkinson’s Drug Candidate
Accure Therapeutics Granted USD 1.6 Million to Advance Parkinson’s Drug Candidate

The Michael J. Fox Foundation for Parkinson’s Research and the Luxembourg National Research Fund have provided funding for two separate projects assessing Accure Therapeutics’ ACT-02 for the treatment of Parkinson’s disease.

New Analysis Strengthens Evidence of Reduced Risk of Dementia with Shingles Vaccination
New Analysis Strengthens Evidence of Reduced Risk of Dementia with Shingles Vaccination

Through analysis of historical vaccination program data, researchers have demonstrated a persistent link between the live-attenuated zoster vaccination and a lower incidence of dementia.

Expansion

Featured
Bora Adds Small-Scale Isolator Line to Baltimore Facility
Bora Adds Small-Scale Isolator Line to Baltimore Facility

The company has added the further sterile fill/finish capacity to the site in response to continued growth in demand for its drug product services.

Ecolab Opens New Bioprocessing Lab in Eastern U.S.
Ecolab Opens New Bioprocessing Lab in Eastern U.S.

The new facility adds to the company’s existing infrastructure and is set to provide comprehensive technical support for bioprocessing to biopharmaceutical companies and contract manufacturers.

Amgen Further Commits to U.S. Manufacturing with Ohio Investment
Amgen Further Commits to U.S. Manufacturing with Ohio Investment

This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.

PCI Expands U.S. Fill/Finish Capabilities with Althea Acquisition
PCI Expands U.S. Fill/Finish Capabilities with Althea Acquisition

The acquisition will provide PCI with a large-scale manufacturing hub on the West Coast of the U.S., complementing its existing global facilities.

Strategy

Featured
Serving as a Gateway to the Americas’ Pharma Market
Serving as a Gateway to the Americas’ Pharma Market

In this interview, Sarah Griffin from Informa Markets provides a review of CPHI Americas 2025 and teases some potential exciting innovations being planned for the 2026 edition of the conference.

Rising Rates of Measles are Highlighting Level of Vaccine Misinformation
Rising Rates of Measles are Highlighting Level of Vaccine Misinformation

While the spread of misinformation about vaccines is contributing to greater vaccine hesitancy, global rates of measles outbreaks are rising at alarming rates, leading to warnings being issued to international travelers.

Reflecting on a Transformative Event for the Americas Pharma Market
Reflecting on a Transformative Event for the Americas Pharma Market

As CPHI Americas wraps up for another year, we look back at some of the highlights from the conference and exhibition hall, and provide a sneak peek of a great opportunity at CPHI Frankfurt.

Novo Nordisk CEO Steps Down
Novo Nordisk CEO Steps Down

The change to the company’s leadership has been expedited as a result of the difficult market conditions and drop in share price that the company has experienced since mid-2024.

Regulatory

Featured
Sarepta Gains Recognition from FDA for its Viral Vector Technology
Sarepta Gains Recognition from FDA for its Viral Vector Technology

As a result of the capability to be used across multiple therapeutic programs, the U.S. regulatory body has granted Sarepta’s AAVrh74 platform with platform technology designation.

Moderna Gains FDA Approval for New Coronavirus Vaccine
Moderna Gains FDA Approval for New Coronavirus Vaccine

This approval, which was based on the results of a Phase III trial demonstrating a higher relative efficiency of the new vaccine compared with the old version, marks the third for the company from the FDA.

Novavax’s COVID-19 Jab Gets FDA Approval
Novavax’s COVID-19 Jab Gets FDA Approval

The recombinant protein-based, non mRNA vaccine has been granted full marketing approval to prevent COVID-19 in adults aged 65 years and older and patients aged 12–64 years who are at risk of severe infection due to underlying conditions.

Verastem Gets Nod from FDA for Rare Ovarian Cancer Combo Therapy
Verastem Gets Nod from FDA for Rare Ovarian Cancer Combo Therapy

The oral combination therapy has been shown to provide a significant overall response rate in LGSOC patients with disease progression despite prior systemic treatment.

Upcoming Events

Featured
HPLC 2025

The 54th International Symposium on High Performance Liquid Phase Separations and Related Techniques (HPLC 2025) will be held from Sunday through Thursday, June 15-19, 2025, in Bruges, Belgium.

BIO International Convention 2025

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

Microbiome Movement Summit USA 2025

Returning for its 10th anniversary, the Microbiome Movement Summit remains the premier global gathering for microbiome drug developers, uniting experts across discovery, preclinical, translational, regulatory, and commercial sectors to drive innovation in the microbiome space.

Medical Device Software Development Summit 2025

The MedTech landscape is evolving rapidly, with FDA’s shifting expectations, AI-driven regulations, and global compliance challenges putting pressure on companies to innovate while maintaining security and compliance.